Altimmune Q3 Loss Widens to $31.6M, Missing Estimates as Trial Costs Climb
ALT is trading near its 52-week low of $1.9 (0.8% above the low).
Summary
Altimmune posted a Q3 net loss of $31.6 million, or $0.15 a share, wider than the $25.48 million consensus and well above the $19.0 million loss a year ago. Operating expenses ran $35.71 million with R&D at $27 million, driven by the Phase 3 PERFORMA MASH trial and the Phase 2 RESTORE ALD trial, plus higher compensation and professional services costs. Cash, equivalents and investments stood at $480 million at quarter end, down from $519 million at the end of Q2 — a modest burn relative to the balance sheet, so dilution is not an immediate concern. The miss is a cost-line story, not a pipeline setback: PERFORMA is on track with 52-week topline in 2029, RESTORE topline is expected in the second half of 2027, and an end-of-Phase 2 meeting with the FDA for the AUD program is set for December 2026. With the stock at $1.92 near its 52-week low of $1.90, the December FDA meeting is the next scheduled item that can change the story.
At the time of this announcement, ALT was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $375.4M. The 52-week trading range was $1.90 to $6.44. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.